Hematology/Oncology

Top Story

NYU Langone appoints neuro-oncology chief

August 30, 2015

Andrew S. Chi, MD, PhD, has been appointed chief of neuro-oncology at NYU Langone Medical Center’s Laura and Isaac Perlmutter Cancer Center.

Chi, a physician-scientist and brain tumor specialist, also will serve as co-director of the NYU Langone Brain Tumor Center.

Institution Notes

MD Anderson appoints orthopedic oncology department chair

August 29, 2015
Valerae O. Lewis, MD, has been named chair of the department of orthopedic oncology at The University of Texas MD Anderson Cancer Center.Lewis, whose clinical focus is…
Timothy J. Ley, MD In the Journals

Persistent mutations may predict EFS, OS outcomes in AML

August 28, 2015
Persistent leukemia-associated mutations in at least 5% of bone marrow cells in day 30 remission samples appeared to significantly increase the risk for relapse and…
Allison W. Kurian, MD, MSc In the Journals

Impact of recurrence score assay on chemotherapy receipt varies based on breast cancer risk

August 28, 2015
The use of a 21-gene recurrence score assay appeared associated with greater use of chemotherapy in patients with low-risk breast cancer and a reduced use of…
In the Journals

Risk protocol identifies patients with cancer not allergic to carboplatin, oxaliplatin

August 28, 2015
Patients with cancer who had a history of presumed carboplatin- and oxaliplatin-induced hypersensitivity reaction did not appear allergic to the chemotherapy drugs after…
More News Headlines »
CME
Hematology Oncology Case Consults

The Patient with Invasive Breast Cancer

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with invasive breast cancer.
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
Tailored Therapies for Myelodysplastic Syndromes

Tailored Therapies for Myelodysplastic Syndromes

This activity is supported by an educational grant from Celgene Corporation.

Myelodysplastic syndromes (MDS) represent a group of myeloid clonal hemopathies with heterogeneous clinical…
More »